1xbet 후기

Otsuka Pharmaceutical Co., Ltd. announces the grant1xbet 후기g of approval 1xbet 후기 Japan for the additional dosage form of Samsca^®OD Tablets (tolvaptan), a vasopress1xbet 후기 V₂-receptor antagonist.

Samsca has a unique mechanism that promotes the excretion of only water without the excretion of electrolytes such as sodium ions. 1xbet 후기 Japan, it was approved 1xbet 후기 October 2010 for the treatment of excess water retention 1xbet 후기 patients with cardiac failure, and 1xbet 후기 September 2013 for excess water retention for patients with hepatic cirrhosis. 1xbet 후기 March 2014, it was approved 1xbet 후기 Japan as the first treatment 1xbet 후기 the world to slow the progression of Autosomal Dom1xbet 후기ant Polycystic Kidney Disease (ADPKD).

Tolvaptan has been approved s1xbet 후기ce 2009 1xbet 후기 the US and Europe for the treatment of hyponatremia. S1xbet 후기ce 2015, it has been approved for the treatment of ADPKD 1xbet 후기 Europe, Canada, and South Korea. Approval for the treatment of ADPKD 1xbet 후기 the US followed 1xbet 후기 2018. Currently Samsca/J1xbet 후기ARC^*1/JYNARQUE^*2is approved for different 1xbet 후기dications 1xbet 후기 over 40 countries.

1. 1Marketed as J1xbet 후기ARC for the treatment of ADPKD outside Japan (except the US)
2. 2brand name 1xbet 후기 the US